Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6529
    +0.0011 (+0.16%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin AUD

    106,991.04
    -2,191.39 (-2.01%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6046
    +0.0012 (+0.19%)
     
  • AUD/NZD

    1.0907
    +0.0005 (+0.04%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     

Is It Too Late to Buy Longeveron Stock?

Is It Too Late to Buy Longeveron Stock?

Up nearly 400% in the last month alone, Longeveron (NASDAQ: LGVN) is doubtlessly one of the more volatile biotechs in the longevity space. Between its brief dalliance with meme stock traders in November and recent progress with regulatory authorities, plenty of people have made a lot of money on the stock. The key fact for investors to know about Longeveron is that it's a young biotech without any late-stage projects.